Licensing opportunity | Development opportunity
Marseille-based Trophos SA has announced that its compound TRO40303 significantly reduces myocardial infarct size and improves cardiac function, and says it is now seeking partners for the programme.
TRO40303 is scheduled to enter clinical development in early 2010, followed rapidly by a Phase II proof of concept clinical trial. Trophos has received a grant to fund the programme from France’s Agence Nationale de la Recherche.
“These new data demonstrate that TRO40303 protects the myocardium against ischemia-reperfusion injury. This protection is at least in part mediated by prevention of opening of the mitochondrial permeability transition pore, recently validated in the clinic as a target for myocardial protection,” said Trophos CEO, Damian Marron.
Despite the use of treatments such as thromobolytics and stents, there is still a great need to reduce morbidity and mortality following myocardial infarction, Marron added. “TRO40303 could represent a new approach and we are actively seeking partners to help us exploit this promise.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
